DK3247791T3 - Universal dræber-t-celle - Google Patents

Universal dræber-t-celle Download PDF

Info

Publication number
DK3247791T3
DK3247791T3 DK16701339.0T DK16701339T DK3247791T3 DK 3247791 T3 DK3247791 T3 DK 3247791T3 DK 16701339 T DK16701339 T DK 16701339T DK 3247791 T3 DK3247791 T3 DK 3247791T3
Authority
DK
Denmark
Prior art keywords
killer
universal
cell
universal killer
Prior art date
Application number
DK16701339.0T
Other languages
Danish (da)
English (en)
Inventor
Gustav Gaudernack
Sébastien Wälchli
Else Marit Inderberg
Gunnar Kvalheim
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Application granted granted Critical
Publication of DK3247791T3 publication Critical patent/DK3247791T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4225Growth factors
    • A61K40/4229Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4244Enzymes
    • A61K40/4246Telomerase or [telomerase reverse transcriptase [TERT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • A61K40/4272Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28Expressing multiple CARs, TCRs or antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/99Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16701339.0T 2015-01-23 2016-01-22 Universal dræber-t-celle DK3247791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (1)

Publication Number Publication Date
DK3247791T3 true DK3247791T3 (da) 2022-07-11

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16701339.0T DK3247791T3 (da) 2015-01-23 2016-01-22 Universal dræber-t-celle

Country Status (17)

Country Link
US (2) US11155786B2 (enExample)
EP (3) EP4681735A3 (enExample)
JP (1) JP6899333B2 (enExample)
KR (1) KR102479118B1 (enExample)
CN (1) CN107250351A (enExample)
AU (2) AU2016208475B2 (enExample)
CA (1) CA2973924C (enExample)
DK (1) DK3247791T3 (enExample)
EA (1) EA201791381A1 (enExample)
ES (1) ES2922231T3 (enExample)
GB (1) GB201501175D0 (enExample)
IL (1) IL253464B (enExample)
MX (1) MX390756B (enExample)
PL (1) PL3247791T3 (enExample)
PT (1) PT3247791T (enExample)
SG (1) SG11201705693XA (enExample)
WO (1) WO2016116601A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11752172B2 (en) 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CN112912727A (zh) * 2018-08-31 2021-06-04 因维克蒂斯股份有限公司 评估car功能性的方法
WO2020191358A1 (en) * 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
WO2021021930A1 (en) 2019-07-29 2021-02-04 Massachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
BR112023005318A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de célula t específicos de prame e uso dos mesmos
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
EP4404956B1 (en) 2021-09-21 2026-04-01 Oslo Universitetssykehus HF Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN121358493A (zh) 2023-06-20 2026-01-16 泽卢纳免疫疗法公司 增强或修饰nk细胞的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
EP1809738B1 (en) * 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2013126785A1 (en) * 2012-02-22 2013-08-29 Ingenium Biotherapy Corporation A system for immunotherapy targeting tumor propagation and progression
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN105378078B (zh) 2013-02-04 2019-03-01 罗杰威廉姆斯医疗中心 用于治疗胃肠道间质瘤(gist)的方法和组合物
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法
CN106459916A (zh) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 作为细胞治疗剂的car‑表达nk‑92细胞
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Also Published As

Publication number Publication date
EP4681735A3 (en) 2026-03-25
EP3247791B1 (en) 2022-05-04
EA201791381A1 (ru) 2018-02-28
PL3247791T3 (pl) 2022-09-05
SG11201705693XA (en) 2017-08-30
NZ733855A (en) 2023-10-27
EP4095239A1 (en) 2022-11-30
CA2973924C (en) 2024-06-04
US20220127574A1 (en) 2022-04-28
BR112017015631A2 (pt) 2018-03-13
ES2922231T3 (es) 2022-09-12
US20180010097A1 (en) 2018-01-11
KR20170121178A (ko) 2017-11-01
US11155786B2 (en) 2021-10-26
MX390756B (es) 2025-03-04
WO2016116601A1 (en) 2016-07-28
GB201501175D0 (en) 2015-03-11
KR102479118B1 (ko) 2022-12-16
IL253464A0 (en) 2017-09-28
AU2022200126A1 (en) 2022-02-10
MX2017009459A (es) 2018-04-11
IL253464B (en) 2022-04-01
JP2018512047A (ja) 2018-05-10
PT3247791T (pt) 2022-07-20
CN107250351A (zh) 2017-10-13
CA2973924A1 (en) 2016-07-28
JP6899333B2 (ja) 2021-07-07
EP3247791A1 (en) 2017-11-29
EP4681735A2 (en) 2026-01-21
AU2016208475B2 (en) 2021-10-14
AU2016208475A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
NO2025002I1 (no) Sugemalimab
IL253464B (en) Universal killer t-cell
EP3858365C0 (en) T CAR CELLS OPTIMIZED WITH GOLD
EP3374114A4 (en) WORKBENCH
HUE046262T2 (hu) Sejt
PL3118311T3 (pl) Antysensowny kwas nukleinowy
DK3283625T3 (da) Nukleasemedieret genomeditering
HUE053101T2 (hu) Javított T-sejt-készítmények
DK3218519T3 (da) Multipass-sekvensering
DK4032440T3 (da) Låganordning
DK3277719T3 (da) Polypeptider
PL3509156T3 (pl) Roztwór elektrolitu
DK3341303T3 (da) Blisterpakning
EP3037812C0 (en) ENZYME ELECTRODE
DK3766582T3 (da) Cellekultur
DK3184642T3 (da) Gærcelle
DK3270930T3 (da) Præeklampsi
PT3353336T (pt) Elétrodo
DK3274482T3 (da) Stenborsknop
DE112015006486A5 (de) Inkubationsrinne
DE102015206660A8 (de) Plattenaufteilanlage
DE112015005906A5 (de) Gurtschlossbringer
DK3390621T3 (da) Forbedret fermentering
DE112016005599A5 (de) Strahlungsgrill
EP3307242A4 (en) PICn-01